DK200600811A - Konstruktion af c-dna af alfavirus af salmonider - Google Patents

Konstruktion af c-dna af alfavirus af salmonider Download PDF

Info

Publication number
DK200600811A
DK200600811A DK200600811A DKPA200600811A DK200600811A DK 200600811 A DK200600811 A DK 200600811A DK 200600811 A DK200600811 A DK 200600811A DK PA200600811 A DKPA200600811 A DK PA200600811A DK 200600811 A DK200600811 A DK 200600811A
Authority
DK
Denmark
Prior art keywords
alphavirus
nucleotides
sequence
salmonide
recombinant dna
Prior art date
Application number
DK200600811A
Other languages
English (en)
Inventor
Bremont Michel
Moriette Coralie
Leberre Monique
Original Assignee
Inst Nat Rech Agrononmique Inr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Rech Agrononmique Inr filed Critical Inst Nat Rech Agrononmique Inr
Publication of DK200600811A publication Critical patent/DK200600811A/da
Application granted granted Critical
Publication of DK177330B1 publication Critical patent/DK177330B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (13)

1. Rekombinant DNA, som er afledt af genomet af et alfavirus af salmonide, og som omfatter: en transkriptionspromotor, og nedstrøms for promotoren og under tran- skriptionel styring af denne; en spacersekvens på i det mindste 5 nukleotider; C-DNA af genomisk RNA af et alfavirus af salmonide.
2. Rekombinant DNA ifølge krav 1,kendetegnet ved, at spacersekvensen defineres af den generelle formel (I) nedenfor: 5’ X ^ CT G AN G ARX2B2X’2 YG AAAX3B3X’3TH 3’ (I) hvor A, T, G og C har deres sædvanlige betydning; H repræsenterer C, T eller A; Y repræsenterer A eller G; R repræsenterer C eller T; N repræsenterer A, T, G eller C; Χλ repræsenterer en oligonukleotid på i det mindste 3 nukleotider, fortrinsvis mellem 6 og 10 nukleotider, af en sekvens, der er komplementær med enden 5’ af genomet af alfavirusset; X2 repræsenterer en oligonukleotid på i det mindste 3 nukleotider, fortrinsvis mellem 3 og 5 nukleotider af en hvilken som helst sekvens; B2 repræsenterer en oligonukleotid på 4 eller 5 nukleotider af en hvilken som helst sekvens; X’2 repræsenterer en oligonukleotid, der er komplementær med X2; X3 repræsenterer en oligonukleotid på i det mindste 2 nukleotider, fortrinsvis mellem 6 og 10 nukleotider af en hvilken som helst sekvens; B3 repræsenterer en oligonukleotid på 4 eller 5 nukleotider af en hvilken som helst sekvens; X’3 repræsenterer en oligonukleotid, der er komplementær med X3.
3. Rekombinant DNA ifølge et hvilket som helst af krav 1 eller 2,kendeteg-n e t ved, at insertet af C-DNA af alfavirus af salmonide omfatter en eller flere ekspressionskassetter, hvor hver omfatter: et eksemplar af den subgenomiske promotor og nedstrøms for denne subgenomiske promotor og under transkrip-tionel styring af denne en heterolog sekvens, som ønskes udtrykt, eller et kloningssted, der muliggør insertionen af denne sekvens.
4. Fremgangsmåde til fremstilling af et RNA reptikon af aifavirus af salmonide, kendetegnet ved, at den omfatter indførelsen i en værtscelle af et rekom-binant DNA ifølge et hvilket som helst af krav 2 eller 3 og kulturen af denne værtscelle.
5. RNA replikon af et alfavirus af salmonide, som kan opnås ved hjælp af en fremgangsmåde ifølge krav 4.
6. Fremgangsmåde til fremstilling af et rekombinant alfavirus af salmonide, kendetegnet ved, at den omfatter indførelse af et rekombinant DNA ifølge et hvilket som helst af krav 2 eller 3 eller et RNA replikon ifølge krav 5 i en værts-celle, hvor alle strukturelle proteiner af dette alfavirus, som er nødvendige for dets indkapsling, og kulturen af denne værtscelle er udtrykt.
7. Fremgangsmåde ifølge krav 6, kendetegnet ved, at alle de genetiske informationer, som muliggør ekspressionen af de strukturelle proteiner, bæres af det rekombinante DNA eller af RNA replikonet.
8. Fremgangsmåde ifølge krav 6, kendetegnet ved, at alle eller dele af de genetiske informationer, som muliggør ekspressionen af de strukturelle proteiner, leveres i trans af værtscellen.
9. Rekombinant alfavirus af salmonide, som kan opnås ved en fremgangsmåde ifølge et hvilket som helst af krav 6 til 8.
10. Anvendelse af et rekombinant DNA ifølge et hvilket som helst af krav 1 til 3 af et RNA replikon af alfavirus af salmonide ifølge krav 5 eller af et rekombinant alfavirus af salmonide ifølge krav 9 med henblik på at opnå en vaccine.
11. Vaccine, som omfatter et rekombinant DNA ifølge et hvilket som helst af krav 1 til 3.
12. Vaccine, som omfatter et RNA replikon af alfavirus af salmonide ifølge krav 5.
13. Vaccine, som omfatter et rekombinant alfavirus af salmonide ifølge krav 9.
DKPA200600811A 2005-06-21 2006-06-15 Konstruktion af c-dna af alfavirus af salmonider DK177330B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0506275 2005-06-21
FR0506275A FR2887259B1 (fr) 2005-06-21 2005-06-21 CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES

Publications (2)

Publication Number Publication Date
DK200600811A true DK200600811A (da) 2006-12-22
DK177330B1 DK177330B1 (da) 2013-01-14

Family

ID=35809739

Family Applications (1)

Application Number Title Priority Date Filing Date
DKPA200600811A DK177330B1 (da) 2005-06-21 2006-06-15 Konstruktion af c-dna af alfavirus af salmonider

Country Status (9)

Country Link
US (3) US8603491B2 (da)
EP (1) EP1907535B1 (da)
JP (1) JP5284086B2 (da)
AU (1) AU2006260796B2 (da)
CA (1) CA2612362C (da)
DK (1) DK177330B1 (da)
FR (1) FR2887259B1 (da)
NO (1) NO342179B1 (da)
WO (1) WO2006136704A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2887259B1 (fr) * 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
CL2015002907A1 (es) * 2015-09-29 2016-06-17 Univ Santiago Chile Vacuna oral contra isav que comprende nanopartículas de quitosán que encapsulan una virina del virus isa y nanoparticulas de quitosán que encapsulan un adyuvante que consiste en un adn que se codifica para la replicasa/transcriptasa de un alfavirus de salmón (replicón), proceso de preparación, método para tratar peces infectados con isav y método para estimular la respuesta inmune en peces.
CN108778365B (zh) 2016-01-11 2021-05-25 沃达瑞公司 微针组合物及其使用方法
NO344938B1 (en) * 2018-12-13 2020-07-20 Patogen As Pancreas Disease Virus Markers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236975T1 (de) * 1992-07-02 2003-04-15 Sankyo Co Haarnadelförmiges ribozym
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
CA2303768C (en) * 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
DE69936774D1 (de) * 1998-05-08 2007-09-20 Intervet Int Bv Strukturproteine des virus, welches die pankreas-krankheit bei fischen verursacht, und ihre verwendungen
WO2002018585A2 (en) * 2000-08-29 2002-03-07 Wyeth Holdings Corporation Packaging of positive-strand rna virus replicon particles
JP2006500012A (ja) * 2002-07-31 2006-01-05 ヌクレオニクス インコーポレーティッド 二本鎖ｒｎａの構造および構築物、並びにその作製法および使用法
FR2887259B1 (fr) 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES

Also Published As

Publication number Publication date
CA2612362A1 (fr) 2006-12-28
FR2887259B1 (fr) 2007-09-14
US20080317777A1 (en) 2008-12-25
US20110064767A1 (en) 2011-03-17
JP5284086B2 (ja) 2013-09-11
DK177330B1 (da) 2013-01-14
EP1907535B1 (fr) 2012-09-12
NO342179B1 (no) 2018-04-09
US9611300B2 (en) 2017-04-04
AU2006260796A1 (en) 2006-12-28
JP2008546399A (ja) 2008-12-25
FR2887259A1 (fr) 2006-12-22
CA2612362C (fr) 2013-10-29
AU2006260796B2 (en) 2010-10-28
WO2006136704A2 (fr) 2006-12-28
EP1907535A2 (fr) 2008-04-09
US20140242114A1 (en) 2014-08-28
WO2006136704A3 (fr) 2007-03-15
US8603491B2 (en) 2013-12-10
NO20076452L (no) 2008-03-07

Similar Documents

Publication Publication Date Title
Aubry et al. Single-stranded positive-sense RNA viruses generated in days using infectious subgenomic amplicons
Flick et al. Rescue of Hantaan virus minigenomes
KANAMORI et al. A tertiary structure model of the internal ribosome entry site (IRES) for methionine-independent initiation of translation
van der Sanden et al. Detection of recombination breakpoints in the genomes of human enterovirus 71 strains isolated in the Netherlands in epidemic and non-epidemic years, 1963–2010
JP2011004755A5 (da)
Zhou et al. The analysis of codon bias of foot-and-mouth disease virus and the adaptation of this virus to the hosts
Fajardo Jr et al. Disruption of specific RNA-RNA interactions in a double-stranded RNA virus inhibits genome packaging and virus infectivity
WO2008142479A3 (en) Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
JP2013507935A5 (da)
JP2008515450A5 (da)
Flick et al. Functional analysis of the noncoding regions of the Uukuniemi virus (Bunyaviridae) RNA segments
Tuo et al. Generation of stable infectious clones of plant viruses by using Rhizobium radiobacter for both cloning and inoculation
DK200600811A (da) Konstruktion af c-dna af alfavirus af salmonider
ES2606605T3 (es) Vacuna para el BVDV
Conradie et al. Establishment of different plasmid only-based reverse genetics systems for the recovery of African horse sickness virus
Wu et al. Biased Pol II fidelity contributes to conservation of functional domains in the Potato spindle tuber viroid genome
CA2968430C (en) Plasmids and method for obtaining viral particles
CN112501138A (zh) 用于快速制备感染性rna病毒的方法
Ido et al. White clover mosaic virus-induced gene silencing in pea
Zhou et al. Characteristics of codon usage bias in two regions downstream of the initiation codons of foot-and-mouth disease virus
Lian et al. Recovery of infectious type Asia1 foot-and-mouth disease virus from suckling mice directly inoculated with an RNA polymerase I/II-driven unidirectional transcription plasmid
JP2008546399A5 (da)
Smits et al. Torovirus non-discontinuous transcription: mutational analysis of a subgenomic mRNA promoter
CN110684797B (zh) 基于tcv的同时沉默2个内源基因的vigs载体
Nida'M et al. Rose spring dwarf-associated virus has RNA structural and gene-expression features like those of Barley yellow dwarf virus